NCT06234592 The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock
| NCT ID | NCT06234592 |
| Status | Recruiting |
| Phase | — |
| Sponsor | King's College Hospital NHS Trust |
| Condition | Septic Shock |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2024-01-05 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2024-01-05 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow. This intra-renal perfusion abnormality may be amenable to pharmacological manipulation, which may offer mechanistic insight into the pathophysiology of septic AKI. The aim of the current study is to investigate the effects of vasopressin and angiotensin II on renal microcirculatory perfusion in a cohort of patients with septic shock.
Eligibility Criteria
Inclusion Criteria: * Within 48 hours of intensive care admission * Evidence of suspected or confirmed infection * Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures) * Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of \>0.1mcg/kg/min * Lactate \>2mmol/L at any stage prior to randomisation Exclusion Criteria: * Known intolerance to Sonovue™ contrast medium, vasopressin or angiotensin II * Patients receiving other vasoactive drugs in addition to norepinephrine * Patients with known chronic kidney disease (CKD) stage 4 or 5 (baseline glomerular filtration rate (GFR) \<30mls/min) * Patients receiving extra corporal membrane oxygenation (ECMO) * Patients with acute occlusive coronary syndromes requiring intervention * Patients with mesenteric ischaemia * Patients with a history or presence of aortic dissection or abdominal aortic aneurysm * Patients with Raynaud's syndrome or acute vaso-occlusive conditions * Pregnancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06234592 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06234592 currently recruiting?
Yes, NCT06234592 is actively recruiting participants. Contact the research team at sam.hutchings@nhs.net for enrollment information.
Where is the NCT06234592 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT06234592 clinical trial?
NCT06234592 is sponsored by King's College Hospital NHS Trust. The trial plans to enroll 45 participants.